Krystal Biotech, Inc. (KRYS) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $323.38, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.5% away).
Krystal Biotech is a commercial-stage biotech that develops, manufactures, and commercializes HSV-1-based gene therapies; its lead product VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB), with $730.3M in cumulative net product revenue... Read more
Hold if already holding. Not a fresh buy at $323.38, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.5% away). Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Downgraded from BUY WAIT — price $323.35 has reached target $324.86. No upside to wait for. Score 6.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Krystal Biotech, Inc.
Latest news
- NEWS Krystal Biotech, Inc. (KRYS) earnings expected to grow: What to know ahead of next week's release - MSN — MSN positive
- NEWS Nestlé Joins the Microbiome Therapeutics Innovation Group (MTIG); Krys Araujo‑Torres, MD, MPP to Represent Company - PR — PR Newswire neutral
- NEWS Earnings Preview: KRYS to Report Financial Results Pre-market on May 04 - 富途牛牛 — 富途牛牛 neutral
- NEWS Krystal Biotech EVP, general counsel sells $193,903 in shares - Investing.com — Investing.com negative
- NEWS Krystal Biotech EVP, general counsel sells $193,903 in shares By Investing.com - Investing.com Canada — Investing.com Canada neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $323.38, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.5% away). Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Downgraded from BUY WAIT — price $323.35 has reached target $324.86. No upside to wait for. Target $324.86 (+0.5%), stop $276.52 (−16.9%), A.R:R -1.1:1. Score 6.5/10, moderate confidence.
Take-profit target: $324.86 (+11.7% upside). Target $324.86 (+0.5%), stop $276.52 (−16.9%), A.R:R -1.1:1. Stop-loss: $276.52.
Analyst target reached - limited upside remaining; Near 52-week high (2.5% away); Expensive valuation.
Krystal Biotech, Inc. trades at a P/E of 42.6 (forward 31.5). TrendMatrix value score: 3.6/10. Verdict: Hold.
18 analysts cover KRYS with a consensus score of 4.3/5. Average price target: $323.
What does Krystal Biotech, Inc. do?Krystal Biotech is a commercial-stage biotech that develops, manufactures, and commercializes HSV-1-based gene...
Krystal Biotech is a commercial-stage biotech that develops, manufactures, and commercializes HSV-1-based gene therapies; its lead product VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB), with $730.3M in cumulative net product revenue since 2023 launch. Pipeline includes KB407 (CF, Phase 1) and KB408 (AATD, Phase 1), supported by two in-house CGMP manufacturing facilities.